Skyhawk Therapeutics Advances Global Phase 2/3 HD Trial
BOSTON, Mass. — July 14, 2026 Skyhawk Therapeutics, Inc. has announced a major expansion of its global pivotal Phase...
Capivasertib
Advertisement
Caris Life Sciences Expands PTEN Testing for Prostate Cancer
IRVING, Texas — July 14, 2026 Caris Life Sciences has expanded its precision oncology portfolio with the launch of...
AstraZeneca’s Truqap Becomes First Targeted Therapy Approved for PTEN-Deficient Prostate Cancer
CAMBRIDGE, United Kingdom, June 12, 2026 AstraZeneca has secured a major regulatory milestone with the U.S. Food and Drug...
Roche Advances Precision Oncology with PTEN Diagnostic Approval
BASEL, Switzerland, June 12, 2026 Roche announced that the U.S. Food and Drug Administration (FDA) has approved the VENTANA...
AstraZeneca TRUQAP Gains FDA Panel Support in Prostate Cancer
WASHINGTON, D.C., April 30, 2026 AstraZeneca announced that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC)...
Advertisement
